Ovarian Neoplasms
📧 Sign up to get email alerts when something new happens for Ovarian Neoplasms.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-08-13Clinical Trial Update: Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) [Phase 2, Phase 3]
Clinical trial update on the efficacy of platinum-based chemotherapy in platinum-resistant ovarian cancer across Phase 2 and Phase 3 stages.
-
CLINICAL_TRIALS trial_result · 2018-08-15Clinical Trial Update: Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma [Phase 2]
Phase II study of DCVAC/OvCa with carboplatin and gemcitabine in relapsed platinum-sensitive epithelial ovarian cancer has completed.
-
EMA withdrawal · 2018-07-13EMA Withdrawn: Topotecan Teva (topotecan) — Teva B.V.
Topotecan Teva has been withdrawn from the market by Teva B.V., affecting indications in ovarian neoplasms, uterine cervical neoplasms, and …
-
CLINICAL_TRIALS trial_result · 2018-06-27Clinical Trial Update: MRI Perfusion in Adnexal Masses
A completed clinical trial evaluating MRI perfusion to characterize complex adnexal masses.
-
CLINICAL_TRIALS trial_result · 2018-04-17Clinical Trial Update: Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors [Phase 2]
Phase 2 trial of pembrolizumab in incurable platinum-refractory germ cell tumors was terminated; results posted in 2018.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2017-11-10EMA Application withdrawn: Kyomarc (bevacizumab) — Amgen Europe B.V.
The EMA withdrew the application for Kyomarc (bevacizumab) from Amgen Europe B.V., relating to several carcinomas and neoplasms.
-
CLINICAL_TRIALS research · 2017-08-29Clinical Trial Update: Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
This completed trial from Göteborg University evaluated new biomarkers and diagnostic algorithms to improve differentiation of ovarian cysts…
-
CLINICAL_TRIALS research · 2017-07-26Clinical Trial Update: EURAD-MR Classification : European Multicenter Study
Clinical trial update for EURAD-MR, a European multicenter study investigating ovarian tumors. The trial status is currently unknown.
-
CLINICAL_TRIALS trial_result · 2017-04-14Clinical Trial Update: A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Advanced Ovarian Cancer [Phase 2]
Phase 2 trial evaluating liposomal doxorubicin with or without olaratumab (IMC-3G3) in platinum-refractory or resistant advanced ovarian can…
-
EMA withdrawal · 2016-12-21EMA Application withdrawn: Zemfirza (cediranib maleate) — AstraZeneca AB
The EMA indicates the Zemfirza (cediranib maleate) application has been withdrawn by AstraZeneca AB for ovarian neoplasms.
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: A Study Of PF-06263507 In Patients With Advanced Solid Tumors [Phase 1]
Phase 1 trial of PF-06263507 in advanced solid tumors has been terminated; results posted.
-
CLINICAL_TRIALS trial_result · 2016-06-03Clinical Trial Update: Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer [Phase 2]
Phase 2 dose-finding trial comparing a PARP inhibitor with Doxil in BRCA-positive advanced ovarian cancer has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2015-12-31Clinical Trial Update: Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer [Phase 2]
Phase 2 efficacy and safety study of ZK219477 for recurrent ovarian cancer has completed; Bayer is sponsor.
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Neocepri (folic acid) — Endocyte Europe, B.V.
The EMA withdrew the application for Neocepri (folic acid) by Endocyte Europe, B.V., with therapeutic areas including ovarian neoplasms and …
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Folcepri (Etarfolatide) — Endocyte Europe, B.V.
EMA withdrawal of the Folcepri (Etarfolatide) application by Endocyte Europe, B.V. for indications in ovarian neoplasms and radionuclide ima…
-
EMA withdrawal · 2014-08-14EMA Application withdrawn: Vynfinit — Endocyte Europe, B.V.
The EMA withdrew the application for Vynfinit (Endocyte Europe, B.V.) for ovarian neoplasms.
-
CLINICAL_TRIALS trial_result · 2014-07-24Clinical Trial Update: An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
A completed clinical trial analyzing the response of human tumor microvascular endothelium to ionizing radiation. The study focused on ovari…
-
CLINICAL_TRIALS trial_result · 2014-05-09Clinical Trial Update: Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer [Phase 2]
A Phase 2 efficacy study evaluating additional intraperitoneal chemotherapy for ovarian neoplasms was terminated; no results are provided in…
-
CLINICAL_TRIALS trial_result · 2014-04-09Clinical Trial Update: Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pancreatic Cancer (PC) [Phase 1, Phase 2]
Phase 1/2 trial evaluating low dose upper abdominal radiation therapy with gemcitabine in advanced, unresectable pancreatic cancer; study co…
-
CLINICAL_TRIALS research · 2013-12-13Clinical Trial Update: Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy [Phase 3]
This document provides an update on a Phase 3 clinical trial evaluating long-term prevention of postoperative nausea and vomiting in gynecol…
-
CLINICAL_TRIALS trial_result · 2013-01-10Clinical Trial Update: AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites [Phase 2]
Phase 2 trial of AVE0005 (VEGF Trap) in patients with recurrent symptomatic malignant ascites due to ovarian neoplasms; results were posted …
-
CLINICAL_TRIALS withdrawal · 2010-04-27Clinical Trial Update: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy [Phase 3]
A Phase 3 trial comparing Caelyx (pegylated liposomal doxorubicin) to paclitaxel HCl in epithelial ovarian carcinoma after failure of first-…
-
EMA withdrawal · 2010-03-22EMA Withdrawn: Paxene (paclitaxel) — Norton Healthcare Ltd.
Paxene (paclitaxel) is withdrawn from consideration by Norton Healthcare Ltd., affecting indications including sarcoma (Kaposi), non-small c…
-
CLINICAL_TRIALS trial_result · 2010-02-26Clinical Trial Update: Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms [NA]
This document notes a completed clinical trial evaluating vasopressin in the vascular tissue associated with ovarian neoplasms.
-
EMA withdrawal · 2009-12-31EMA Withdrawn: Indimacis 125 (igovomab) — CIS bio international
EMA status indicates Indimacis 125 (igovomab) has been withdrawn from the market.